Abstract 48P
Background
Sentinel lymph node biopsy (SLNB) in post-neoadjuvant chemotherapy (NACT) has demonstrated a higher false negative rate (FNR) compared to early breast cancer. This might result from a non-uniform pattern of tumour regression in SLN and Non-SLN within the axilla. SLNB can assess SLN alone by itself, but preoperative axillary ultrasound (AUS) can also determine the characteristics of Non-SLN. We studied whether axillary staging in post-NACT patients could be improved by combining AUS and SLNB to reduce false negative cases.
Methods
It was a single-centre, prospective study that was conducted between September 2020 and June 2022. All Post-NACT, clinically node-negative(cN0) patients who were scheduled for surgery were enrolled and underwent AUS. AUS normal node patients underwent SLNB using fluorescein and methylene blue followed by Axillary Lymph Node Dissection (ALND). We evaluated the AUS's Positive Predictive Value (PPV), Negative Predictive Value (NPV) and FNR in cN0 patients. The FNR of SLNB was calculated in patients who had cN0 and AUS normal nodes.
Results
cN0 was found in 62 patients out of 136 post-NACT patients.AUS had PPV and NPV of 90.6% and 76.6%, respectively. The FNR for AUS alone was 19.4% (7/36). Loss of fatty hilum was found to have a PPV of 89.3% and a sensitivity of 70%, making it the most reliable marker of nodal metastasis. Methylene blue allergy was observed in 1 patient. The FNR of SLNB was 8.6% (2/23) for the patients who had been selected for SLNB based on AUS normal nodes.
Conclusions
AUS alone or SLNB alone is insufficient to determine axilla node-negative status and can't omit ALND because each has a high FNR (>10%). If AUS findings are considered for selecting patients for SLNB, it reduces its FNR to below 10% and improves the accuracy of axillary staging in post-NACT patients.
Clinical trial identification
Clinical Trials Registry (India) number- CTRI/2020/10/028337.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract